{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:49:36Z","timestamp":1768686576643,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004945","name":"Nankai University","doi-asserted-by":"publisher","award":["2023JCYBJC0800"],"award-info":[{"award-number":["2023JCYBJC0800"]}],"id":[{"id":"10.13039\/501100004945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bmc.2025.118175","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:06:10Z","timestamp":1743134770000},"page":"118175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of novel transforming growth factor \u03b2 type 1 receptor inhibitors through structure-based virtual screening, preliminary structure\u2013activity relationship study, and biological evaluation in hepatocellular carcinoma"],"prefix":"10.1016","volume":"123","author":[{"given":"Siyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhou","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdisamat","family":"Ababakri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-6760","authenticated-orcid":false,"given":"Wentao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118175_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-\u03b2 and the TGF-\u03b2 Family: Context-Dependent Roles in Cell and Tissue Physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bmc.2025.118175_b0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118175_b0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF\u03b2 signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2025.118175_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00441-011-1199-1","article-title":"Deconstructing the mechanisms and consequences of TGF-\u03b2-induced EMT during cancer progression","volume":"347","author":"Wendt","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.bmc.2025.118175_b0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri.2016.112","article-title":"Immunoregulation by members of the TGF\u03b2 superfamily","volume":"16","author":"Chen","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2025.118175_b0030","first-page":"127","article-title":"TGF-\u03b2 function in immune suppression","volume":"350","author":"Yoshimura","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.bmc.2025.118175_b0035","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9732939","article-title":"Transforming of the Tumor Microenvironment: Implications for TGF-\u03b2 Inhibition in the Context of Immune-Checkpoint Therapy","volume":"2018","author":"L\u00f6ffek","year":"2018","journal-title":"J Oncol"},{"key":"10.1016\/j.bmc.2025.118175_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2836-1","article-title":"TGF-\u03b2 suppresses type 2 immunity to cancer","volume":"587","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118175_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41586-020-2850-3","article-title":"Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in T(H) cells","volume":"587","author":"Li","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118175_b0050","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257453","article-title":"Novel TGF-\u03b2 inhibitors ready for prime time in onco-immunology","volume":"6","author":"de Gramont","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bmc.2025.118175_b0055","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7","volume":"65","author":"DaCosta","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118175_b0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/sj.bjp.0706172","article-title":"Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis","volume":"145","author":"de Gouville","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118175_b0065","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1158\/1078-0432.CCR-06-0162","article-title":"Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo","volume":"12","author":"Ge","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118175_b0070","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/jpet.104.082099","article-title":"Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis","volume":"313","author":"Grygielko","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118175_b0075","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/mol.105.021600","article-title":"Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression","volume":"70","author":"Kapoun","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118175_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","article-title":"Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice","volume":"44","author":"Bueno","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2025.118175_b0085","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118175_b0090","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/acsmedchemlett.9b00552","article-title":"Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF\u03b2R1 Inhibitor as an Immuno-oncology Agent","volume":"11","author":"Velaparthi","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118175_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128979","article-title":"Discovery of MDV6058 (PF-06952229), a selective and potent TGF\u03b2R1 inhibitor: Design, synthesis and optimization","volume":"75","author":"Pujala","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118175_b0100","series-title":"Edited by USA","article-title":"Preparation of aminopyridyloxypyrazole compounds as TGF\u03b2R1 inhibitors","author":"Mcmillen","year":"2016"},{"key":"10.1016\/j.bmc.2025.118175_b0105","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2025.118175_b0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2025.118175_b0115","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118175_b0120","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2025.118175_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112354","article-title":"Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-\u03b2 type 1 receptor inhibitors","volume":"198","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118175_b0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:56:53Z","timestamp":1762347413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"alternative-id":["S0968089625001166"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118175","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel transforming growth factor \u03b2 type 1 receptor inhibitors through structure-based virtual screening, preliminary structure\u2013activity relationship study, and biological evaluation in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118175"}}